Tag Archives: clinical trial


Another treatment option coming down the pike: TAS-102

Another treatment option coming down the pike: TAS-102

Fight Colorectal Cancer stays actively involved in the research process from beginning to end. Part of our role in research is monitoring the progress of new drugs – drugs that may be used in treatment plans of colorectal cancer in the future. We actively work with drug companies to stay up-to-date on the latest treatments so that we can let patients and families know what’s happening in the science of colorectal cancer. For the last year, Fight Colorectal Cancer staff have tracked the progress of the drug TAS-102 – an oral chemo drug currently being evaluated in clinical trials for patients with metastatic refractory colorectal cancer. At the ESMO World


Meet the One Million Strong – Diana Welch from Maryland

Be a part of One Million Strong and tell us how colorectal cancer has impacted your life! Share your story now!  MEET DIANA Diana Welch, Survivor Huntingtown, MD DIANA’S STORY After several months of severe upper abdominal pain and learning to be my own advocate, I was diagnosed with stage IV colon cancer in March 2012.   This was followed by a diagnosis of Celiac Disease just two months prior.  After meeting with a nutritionist and changing to a gluten free diet, my symptoms persisted and worsened  and I continued to seek out a doctor that would be able to further  diagnose my symptoms.  A colonoscopy was the definitive test that

Fight Colorectal Cancer, National Cancer Institute recruit colon cancer survivors

FOR IMMEDIATE RELEASE Aug. 2, 2013 - ALEXANDRIA, Va. – Fight Colorectal Cancer is working with The National Cancer Institute (NCI) to recruit participants for a new study testing informed consent documentation. Study participants will evaluate an informed consent document (ICD) that explains a clinical trial and determine its clarity and ease of use. Participants will be paid $40 for their time. The study is looking for 50 MALE SURVIVORS to participate before Aug. 31, 2013. Study results will help NCI finalize a new informed consent document for future patients considering a clinical trial. NCI chose to work with Fight Colorectal Cancer because the ICD is written for a colon cancer clinical trial. Those

New Trial Looks to Reduce Recurrence and Neuropathy for Stage III Patients

If you are diagnosed with stage III colon cancer, you will probably receive about six months of treatment with FOLFOX after surgery. Research shows that this treatment regimen helps prevent recurrence for some – but not all – patients with stage III colon cancer.  A clinical trial has been launched to answer two questions about this current standard of care: 1. Will recurrence rates go down if both FOLFOX and celecoxib (a non-steroidal anti-inflammatory drug similar to aspirin) are used for treatment? 2.  Will recurrence rates stay the same and long term side effects decrease if FOLFOX is used for three months?

CRC Groups Join Together to Offer Clinical Trial Matching

Leading colorectal cancer advocacy organizations Colon Cancer Alliance and Fight Colorectal Cancer announced that they are teaming up on an initiative to encourage patients with colorectal cancer to take charge of their diagnosis and learn about clinical trials. The Colorectal Cancer Clinical Trial Call to Action campaign matches colorectal cancer patients with currently recruiting clinical trials based on their individual medical situation. The easy-to-use resources, powered by EmergingMed, help patients discuss with their doctor clinical trials that may be appropriate for them.  The personalized service is free, confidential, and available to patients, loved ones and healthcare professionals. “Patients who participate in clinical trials also help further colorectal cancer research,” said

New Opportunity for Patients Finishing Colon Cancer Treatment

Are you finished with surgery or chemotherapy for early stage colon cancer? Would you like a chance to see if a new experimental treatment can reduce your risk of A new polyp in your colon? Colon cancer spreading beyond your colon? A new colon cancer? Researchers at the National Surgical Adjuvant Breast and Bowel Project (NSABP) would like to talk to you about a clinical trial exploring whether a statin drug can reduce the risk of new polyps, colon cancer recurrence, or a new primary colon cancer. In the P-5 clinical trial stage I and II colon cancer patients will be randomly assigned to take either rosuvastatin (Crestor®) or an